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ABSTRACT
Objectives, setting and patients: With complete case
referral for prolonged parenteral nutrition (PN) beyond
term equivalent, serving a stable population of 1.25 million
people, we describe the long-term outcome and survival
of patients referred to an intestinal failure (IF) nutrition
support team over the first 8 years of existence at a
regional paediatric centre, and extrapolate to potential
numbers of national home parenteral nutrition (HPN)
cases and intestinal transplantation data.
Design and outcome measures: Retrospective analysis
detailing patient demographics, interventions, use of HPN,
occurrence of intestinal failure-associated liver disease
(IFALD), and outcomes of enteral adaptation, survival, and
referral for and receipt of organ transplantation.
Results: 23 patients were referred over 8 years, 20 being
PN dependent within the neonatal period. Diagnoses
included short bowel syndrome (SBS) (18), neuromus-
cular abnormalities (4) and congenital enterocyte disorder
(1). 12 696 days of PN were delivered with 314
confirmed episodes of sepsis at a median of 12 episodes
per patient. 144 central venous catheters (CVCs) were
required at a median of four per patient. IFALD occurred in
17 (73%) patients, with 10 (44%) referred for transplant
assessment. Thirteen (56%) children received HPN.
Overall mortality was 44%. A significant predictor for
survival in the SBS group was residual bowel .40 cm
(82% vs 28%, p = 0.049).
Conclusions: Survival for IF at 56% was lower than
reported from non-UK supra-regional centres, and
nationally collected data, possibly reflecting pre-selected
referral populations. Data from regional centres with
complete ascertainment may be important both when
counselling parents and when planning regional and
national HPN and IF specialist services.
Intestinal failure (IF) is defined as the reduction of
functional gastrointestinal mass below that needed
for digestion and absorption of fluid and nutrients
for maintenance in adults and growth in children.1–3
It can be separated into three main groups by
pathogenesis.4 5 These are: (1) short bowel syndrome
(SBS)6; (2) neuromuscular disorders of the gastro-
intestinal tract including long segment aganglionosis
(Hirschsprung’s disease) and congenital intestinal
pseudo-obstruction syndromes (CIPOS)7; and (3)
congenital enterocyte disorders.8 9 Parenteral nutri-
tion (PN) has dramatically improved the previously
dismal prognosis for this patient population.1 5 10
However, significant complications of management,
such as central line sepsis, intestinal failure-asso-
ciated liver disease (IFALD) and growth failure, have
contributed to long-term morbidity and mortality in
IF.1 5 11 Combined small bowel and liver transplanta-
tion (CSBLT) now offers alternative treatment for
patients surviving with irreversible IF.5 12 Currently,
care for IF in the UK is performed in regional
paediatric gastroenterology and nutrition services
with multidisciplinary nutrition support teams
(NSTs).13 At the time of writing, there is a single
intestinal transplantation unit located at
Birmingham Children’s Hospital. Outside the UK,
national centres of excellence for management of
long-term IF and home parenteral nutrition (HPN)
exist.14 Outcomes for patients with longstanding IF
appear to be improving, as seen from data collected
from national centres of excellence (outside the UK)
and from intestinal transplantation services.14 15
However, there is a paucity of incidence and
outcome data for such patients from regional
centres. This study aimed to describe the incidence,
prevalence and long-term outcome of IF referred to a
regional NST, when all cases from a geographical
region are obtained, and to extrapolate these data for
potential use of national HPN and intestinal
transplant services.
METHODS
Setting and patients
Following the appointment of a consultant in
paediatric gastroenterology and nutrition in
What is already known on this topic
c The prevalence of intestinal failure is rising and
long-term survival of home parenteral nutrition
patients from some national centres has risen to
.90% in recent years
c Intestinal failure-associated liver disease
contributes significantly to long-term morbidity
and mortality of these patients.
What this study adds
c Outcomes from these regional data are poorer
than previously described national data; this may
reflect a fuller ascertainment and thus a greater
burden of disease than currently recognised.
c Regionally obtained data suggest an
underestimate in national resource requirements
for home parenteral nutrition and combined small
bowel and liver transplantation or isolated liver
transplant services.
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August 1997, the Royal Hospital for Sick Children, Edinburgh
(RHSC) developed a multidisciplinary IF NST. This consisted of
a consultant paediatric gastroenterologist, consultant paediatric
surgeons, specialist paediatric nutrition nurse, paediatric dieti-
cians, specialist paediatric pharmacist, ward nursing staff, and
specialist social worker. The RHSC serves as the single tertiary
paediatric unit to the region of southeast Scotland with a stable
population of around 1.25 million, and provides all PN to post-
term infants and children. Referral to the team is made from
within the RHSC (medical or surgical teams), from four other
district general paediatric units, two level three NICU and two
level two neonatal nurseries within the region. The aims of the
team were to optimise the long-term outcome of patients
identified as having IF by maximising enteral nutrition,
facilitating the use of HPN and acting as a point of referral to
UK national transplantation services when required.
In-patients are managed in a combined medical and surgical
ward and are reviewed by the multidisciplinary ward-round on
a daily basis with alterations to therapies and PN being made to
optimise bowel adaptation. PN prescription is conducted in
conjunction with a senior specialist paediatric pharmacist.
Central lines are placed and removed by paediatric surgeons
dedicated to the NST. Training and supervision of line-care by
ward staff, junior doctors and parents is coordinated by a
dedicated nutrition nurse specialist. PN is always cycled to an
optimal level dependent upon age, prematurity and clinical
status. Enteral feeding is modified by the NST specialist
paediatric dietician. As a rule, when available, the mother’s
milk is the first feed. When not tolerated, a semi-elemental feed
is normally trialled, followed if necessary, by a completely
elemental diet. Feeds high in medium-chain triglycerides are
given when a patient is significantly cholestatic. Modular feeds
are reserved for patients with specific indications, such as
suggestion of very low threshold of carbohydrate tolerance.
Bilirubin, liver enzymes and synthetic function are assessed
weekly with micronutrient nutritional screening on a monthly
basis. When IFALD is identified, management involves a
protocol of investigation for other causes of cholestatic liver
disease, a review of enteral and parenteral nutrition and
commencement of ursodeoxycholic acid. A standard sepsis
protocol of broad-spectrum antibiotics for fever .38.5uC or
recurrent fever .38.0uC exists. Individual patient sepsis proto-
cols are established in conjunction with a specialist consultant
microbiologist and are available on the front of patients’ case
notes. The specialist nutrition nurse trains parents to handle PN
and the dedicated social worker identifies and rectifies non-
medical hindrances to discharge. HPN patients are discussed in a
multidisciplinary meeting weekly, with emphasis being placed
on optimising enteral nutrition, sepsis prevention and manage-
ment and quality of life issues. Patients are seen in a dedicated
IF clinic after discharge. We work within the Scottish HPN-
managed clinical network (http://www.shpnmcn.scot.nhs.uk)
which aims to facilitate excellence and standardisation of care
for all HPN patients across Scotland.
Design and outcome measures
Data were obtained retrospectively from the medical records of
patients from the IF NST database, logged prospectively from
August 1997 to June 2005. These data were analysed by
database Excel for Windows (Microsoft Office XP). Entry
criteria were patients referred to the regional paediatric NST
with a primary gastrointestinal disorder, and who must have
received .28 days’ PN by completion of study. Demographic
data obtained for patients at point of referral to the team were
date of birth, age at referral, birth weight, gestational age at
birth, diagnoses, weight at referral and number of days of PN at
referral. Patients were grouped according to cause of IF – SBS,
neuromuscular disease or enterocyte disorder.
SBS patients had additional data recorded for primary
diagnosis. Initial surgical records were reviewed and residual
small bowel length recorded. Where only length of bowel
resected was recorded, an estimated residual bowel length was
calculated using a standardised formula against gestation.16
Other surgical details recorded were: primary anastomoses,
defunctioning stomas, and whether the ileo-caecal valve (ICV)
had been removed. Patients with neuromuscular disease had
primary diagnosis and subsequent surgical procedures noted.
Longitudinal data were then obtained to evaluate patient
management and outcomes in the following categories.
1. PN and enteral adaptation
Recorded items were the total number of days of PN, total
number of semi-permanent tunnelled central venous catheters
(CVCs) required and other complications of PN (line occlusion,
thrombosis, growth failure, pubertal delay, IFALD), proportion
of patients who received HPN, and the number of confirmed
episodes of bacterial/fungal sepsis (defined as clinical signs of
sepsis in combination with a significant growth of appropriate
organism from CVC culture, peripheral line culture or periph-
eral venous culture, with resolution of symptoms with
appropriate antibiotic therapy). Further cultures of the same
organism were not considered to be a separate septic episode
until the patient had remained afebrile for 5 days off antibiotic
treatment. We defined enteral adaptation as ,10% weight loss
after cessation of PN followed by sustained weight gain. Time
to adaptation was recorded in months, and enteral feed regimen
at time of adaptation was also recorded.
2. IFALD, transplantation and outcome
Patients were defined as having IFALD (direct bilirubin
.50 mmol/l)17 or being severely cholestatic (direct bilirubin
.100 mmol/l) either at referral or during their course of
treatment. Criteria for referral to the intestinal transplantation
unit were conjugated bilirubin .150 mmol/l outwith septic
episodes, or progressive fibrotic liver disease on biopsy, lack of
vascular access, poor long-term prognosis or very impaired
quality of life for parents/carers or patients. We noted whether
patients required referral for assessment for CSBLT or isolated
liver transplant (ILT) and if they received this assessment, we
also noted whether patients were then listed for transplanta-
tion, and if so, whether they received transplantation. All
transplantation and transplant assessment was performed at
the UK supra-regional Intestinal Transplant Assessment Centre
at Birmingham Children’s Hospital, Birmingham, UK. Outcome
data recorded included patient survival, death, age at death,
cause of death and death while awaiting organ transplantation.
3. Extrapolation of regional results to national situation
To determine how our data would translate into national
statistics, we calculated our service population to be 2.1% of the
UK (1.25/60 million 6 100%). We then extrapolated what
annual registration of HPN patient, annual referral to the
intestinal transplantation unit, CSBLT and ILT would be based
on these figures ((n6100/2.1)/8 years). We compared our figures
with current published UK data on paediatric HPN registration18
and referral to the intestinal transplantation unit.15
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Normally distributed continuous data are described as mean
(SD), non-normally distributed continuous data are described as
median (range), and categorical data are described as number
(%). All statistical analyses were performed using Minitab V.14
(Microsoft Office XP) and a p value of (0.05 was considered
significant. Ethical approval is not required for this type of
study, confirmed by correspondence with our Local Research
Ethics Committee.
RESULTS
Twenty-three patients were referred to the team (18 SBS, 4
neuromuscular disorders, 1 epithelial disorder). Patients referred
had a median gestation of 35 weeks (range 25–38 weeks), birth
weight of 2.44 kg (range 0.65–3.55 kg), and were referred at a
median age of 2 months (7 days–81 months) having received
35 days’ PN (0–370 days), respectively. (Patient histories are
available as a supplemental file.) Some variability existed in time
to referral as a small proportion of patients were already
established on PN before the creation of the NST. Patient
demographics are summarised in table 1. Out of the SBS cohort,
seven (39%) had residual bowel length ,40 cm, with eight
(44%) having had their ICV removed.
1. PN, sepsis, HPN and adaptation
Twelve thousand six hundred and ninety-six patient days of
PN were delivered at a median of 310 days per patient (range
58–2730 days). Thirteen (56%) patients received HPN. There
were no significant differences in demographic details between
these patients and those in whom adaptation occurred prior to
discharge from hospital. There were 314 confirmed episodes of
bacterial sepsis (median of 12 episodes per patient (2–52)) at a
mean of one septic episode per 40.4 patient days. Bacterial and
fungal growths identified in blood culture are summarised in
table 2.
A total of 144 CVCs were placed (median four per patient
(range 1–24)). Thirteen of 23 patients received HPN. Patients
who achieved HPN had a significantly lower infection rate
in comparison to those who received all PN in the hospital
(1 infection per 45.1 PN days vs 1 per 30.2 PN days, p = 0.023,
95% CI 227.6 to 22.3). CVCs lasted a mean of 80.6 patient
days, and only five CVCs (3%) were removed because of total
line occlusion. We identified three major thrombotic complica-
tions (one right internal jugular thrombosis, one bilateral iliac,
and one vena cava right atrial). No patients were referred for
transplant assessment because of loss of vascular access. Only
10 (44%) patients achieved full enteral adaptation, two of these
being post-CSBLT and one post-ILT. Adaptation was achieved
at a median of 31 months (range 9–47 months).
2. IFALD, organ transplant and outcome
Nine (39%) patients had IFALD at referral with six (27%)
having severe cholestasis. Of the SBS cohort, eight (44%) cases
had already developed IFALD at time of referral with six (33%)
being severely cholestatic. Seventeen (73%) patients developed
cholestasis during the study. Early age of referral to the NST
(,3/12) and frequent episodes of infection (,30 days) posi-
tively correlated with subsequent IFALD development (table 3).
Twelve (52%) patients developed cholestasis reaching levels
which indicated need for referral to the intestinal transplanta-
tion unit in Birmingham for assessment (total bilirubin
consistently .150 mmol/l outwith septic episodes). Ten were
assessed; one family declined assessment and another patient
Table 1 Demographic data of 23 intestinal failure patients referred over 8 years
Patient Diagnosis
Gestation
(weeks)
Birth weight
(kg)
Age referral
(months)
No of days’
PN Cholestatic
Patient 1 SBS (NEC) 28 0.65 1 36 No
Patient 2 SBS (gastroschisis) 36 2.75 3 75 Yes
Patient 3 SBS (NEC) 31 1.38 1 35 Yes
Patient 4 SBS (NEC) 38 2.30 13 370 Yes
Patient 5 SBS (NEC) 32 1.73 21 210 No
Patient 6 Long segment
Hirschsprung’s
39 2.78 16 0 No
Patient 7 SBS (NEC) 30 1500 4 14 No
Patient 8 Congenital enterocyte
disorder
40 3.98 ,1 0 No
Patient 9 Long segment
Hirschsprung’s
38 3.91 3 0 No
Patient 10 SBS (NEC) 33 2.1 2 45 Yes
Patient 11 SBS (SMA thrombosis) 37 3.0 6 0 No
Patient 12 CIPOS 39 3.21 81 0 No
Patient 13 SBS (NEC) 25 0.86 3 90 Yes
Patient 14 SBS (ileal atresia) 35 2.68 ,1 21 No
Patient 15 SBS (gastroschisis) 36 2.44 ,1 3 No
Patient 16 SBS (NEC) 25 0.85 3 55 Yes
Patient 17 SBS (NEC) 29 1.7 2 46 Yes
Patient 18 CIPOS 36 4.1 2 50 Yes
Patient 19 SBS (ileo-jejunal atresia) 36 3.55 2 21 No
Patient 20 SBS (NEC) 30 1.68 4 45 No
Patient 21 SBS (ileal atresia) 35 2.8 ,1 0 No
Patient 22 SBS (meconium ileus) 39 2.8 ,1 12 No
Patient 23 SBS (NEC) 29 1.18 1 43 Yes
Cholestasis was defined as serum bilirubin .30 mmol/l. Patients were referred before commencing PN (ie, were commenced on
PN by the nutrition support team).
CIPOS, congenital intestinal pseudo-obstruction syndromes; NEC, necrotising enterocolitis; PN, parenteral nutrition; SBS, short
bowel syndrome; SMA, superior mesenteric artery.
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died whilst awaiting assessment. Five (22%) patients received
transplants (four CSBLT, one ILT) and two patients died whilst
awaiting transplantation. Three remained on the transplant list
at the close of audit. In total, 10 (44%) patients died. Causes of
death included end-stage liver disease,4 sepsis,2 gastrointestinal
haemorrhage, post-transplant multi-organ failure, renal failure
and cytomegalovirus encephalopathy post-transplant. Median
age of death was 12 months (range 7–107). Significant
predictors for survival in the SBS group were residual bowel
length .40 cm (82% vs 28%, p = 0.049), .3 months’ age at
referral to NST (81% vs 33%, p = 0.036) and proceeding to HPN
(77% vs 30%, p = 0.04) (table 4).
3. Extrapolation of regional results to national situation
We calculated that our total 8-year caseload of 23 patients, 13
HPN patients and 12 patients with indications for referral to
transplantation services extrapolate to 1095, 619 and 571,
respectively, nationally over 8 years. Ten (77%) of our HPN
patients had SBS in comparison with the national average of
40%.18 Eleven out of 12 (92%) of our patients indicated for referral
to transplantation services and 9/10 (90%) of patients referred had
SBS, compared with 89/159 (55%) in the intestinal transplanta-
tion unit.15 Our extrapolated annual national registration of HPN
patients of 77.4 compares with 14.8 (89/6 years) from the BANS
report 2000–200518 and our annual rate of referral to the intestinal
transplantation unit of 71.4 compares with 17.3 (104/6 years)
actual referrals to the intestinal transplantation unit15 (fig 1).
DISCUSSION
IF in the paediatric population now appears to have a better
prognosis in comparison with adults,14 19 with a greater
proportion of patients achieving complete enteral adaptation
over time. PN and HPN are the mainstays of medical therapy
whilst awaiting this adaptation process. Most reviewers relate
increased survival to improved safety of delivery of PN,
development of NST and earlier identification of patients with
irreversible disease or complications such as IFALD that require
referral to transplant services.
On initial reflection our data relating to sepsis rate (1 per
40.4 patient days), severe IFALD (52%), and survival rate (56%)
over 8 years represent disappointing outcomes in comparison
with other published work.14 15 However, this may be partially
attributable to variations in reporting in terms of definition of
IF, and our local case mix. This may then have secondary effects
on complications of IF treatment such as sepsis and develop-
ment of IFALD. IF has been defined in paediatric surveys as any
patient requiring PN for .28 days. Other case series have
included patients without primary intestinal disorders (includ-
ing oncology and intensive care patients requiring PN support
during prolonged courses of inpatient illness), or patients who
have not required PN beyond term.20 HPN is not an issue for
these patients, and they are not candidates for CSBLT. Data
gathered from national centres outside the UK may reflect a pre-
selected group that has demonstrated stability on PN for a
period of time, and thus produces a referral bias which can lead
to improved long-term outcomes.1 15 Other regions may also
have patients with IF being managed beyond term by a service
that would not fulfil the criteria for NST. Our institution serves
a region with a population of 1.25 million; it has a unique
service organisation. As the only centre performing neonatal
surgery for the region, with a single NICU providing PN after
term, and a single NST, we are confident that we have complete
early ascertainment of patients with primary intestinal dis-
orders who have a potential requirement for PN beyond term
(as well as all of the older infants, children and teenagers
requiring PN). These neonatal patients are those who are likely
to require tertiary NST services, as they are the patients who
have the potential to receive HPN and/or require referral to
transplant services.
PN, HPN and adaptation
We reported on over 12 000 patient days of PN with 56% of
patients receiving HPN. Koglmeier et al20 found that only 5% of
IF patients required HPN over 2 years. This difference may in
part be attributed to disease severity in our patients. Only 44%
of our patients achieved enteral adaptation (not all of these
patients required specialist NST input). Factors shown to
predict time to enteral adaptation in SBS include length of
remaining small bowel; a length of >40 cm has been shown to
be a significant factor for earlier adaptation.10 The loss of the
ICV, intestinal inflammation and bacterial overgrowth also
appear to negatively affect adaptation.21 The primary stimulus
for the bowel adaptation process is enteral nutrition, with early
postoperative feeding predicting shortened period of depen-
dency on PN.22 Other studies have reported marked success in
weaning long-term PN patients when instituting an intestinal
rehabilitation programme with Torres et al23 achieving 31/37
HPN patients weaning successfully. This figure falls to 64%
when dealing with neonatal onset diseases as described by
Diamond et al.24 However, the effects of prematurity on
outcome are not described in either cohort.
Table 2 314 positive cultures from central lines from 23 intestinal
failure patients receiving parenteral nutrition
Positive cultures (%)
Coagulase-negative staphylococcus 145 (43)
Enterococcus faecalis 43 (12)
Klebsiella 36 (11)
Enterobacter cloacae 35 (11)
Escherichia coli 18 (5)
Candida 15 (4)
Staphylococcus aureus 12 (3)
Streptococcus 11 (3)
Pseudomonas 10 (3)
Other 11 (3)
Table 3 Intestinal failure-associated liver disease (IFALD) development according to patient characteristics
Comparator IFALD development (%) Significance
NEC vs non-NEC 7/11 (64%) vs 9/12 (75%) p = 0.667
Age ,3/12 vs >3/12 at referral 11/11 (100%) vs 5/12 (42%) p = 0.005
Infection rate ,30 days vs >30 days 9/9 (100%) vs 8/15 (53%) p = 0.022
Preterm vs non-preterm 13/15 (86%) vs 5/8 (63%) p = 0.297
NEC, necrotising enterocolitis.
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Sepsis rates and IFALD
We report a high incidence of bacterial sepsis with a median of
12 episodes of sepsis per patient at a rate of one per 40.4 catheter
days. Clear guidance for the use of long-term CVC for PN
delivery now exists for paediatric patients; the use of dedicated
single lumen subclavian catheters is recommended.25 A dramatic
reduction in bacterial sepsis rates has been shown to be
associated with both non-touch sterile access of catheters, and
having a dedicated PN nurse formally training all ward staff,
medical staff and parents on how to access CVC.25 26 Despite
early institution of these measures our sepsis rate remains
higher than other series; however, the definition of septic
episodes in the literature is often unclear27–29 and there is a lack
of a standardised method of reporting.
In our series 73% of 23 patients developed IFALD and 52%
had indications for referral for transplant assessment. The
relationship between IF, PN and cholestasis is not clear.
Although individual constituents of PN have been shown to
be hepatotoxic,11 30 31 IFALD itself has a multifactorial aetiology.
Patients who are able to take some of their nutrition enterally
appear to have partial protection from IFALD in comparison
with patients who receive all their calories intravenously.22 32 In
addition, a normal functioning small bowel would appear to
protect adult populations against cholestasis when receiving
PN.33 Recurrent bacterial sepsis has been heavily implicated in
the development of IFALD in neonates and children.11 Colomb
et al34 reported a much lower rate of 23% IFALD in HPN
patients, although the proportion of patients who were term or
older children was greater in this cohort. Koglmeier et al20
reported that IFALD complicated 59% of paediatric cases of
IF. Sondheimer et al35 reported a similar incidence of IFALD
(67%) in a series of 42 patients with SBS, and only 17% of these
patients went on to develop liver failure. Our criteria for
transplant assessment are mostly based on serum bilirubin
rather than synthetic liver function, thus making direct
comparison of results inappropriate. Fifty-two per cent of
patients had indications for transplant assessment, 22% of our
patients received organ transplantation, and a further two
patients died on the transplant waiting list. This exceeds the
previously described figure of 15–20% requiring transplanta-
tion.1 This may partly be a reflection of the severity of disease in
our cohort and also the relatively high incidence of bacterial
sepsis predisposing to IFALD development. In our series, 48% of
detected organisms on blood culture were found to be either
Gram negative or fungal, both of which are strong predictors for
IFALD development.35 We suggest that there is a greater burden
of liver disease if all IF patients in a geographical area are
ascertained, rather than the lesser burden suggested by either
nationally gathered data18 or data from a single or small number
of centralised national referral centres.14 15
Outcome
We report only 56% survival over 8 years which is lower than
other recent studies. Diamond et al24 reported 62.5% over 3 years
in an SBS cohort, Colomb et al34 reported 81% survival over 10
years in a paediatric HPN cohort, and Koglmeier et al20 reported
94% survival over 2 years in a paediatric IF series. We would,
however, again suggest that the differences in patient ascertain-
ment and patient mix, namely high rates of early referral,
prematurity and NEC (48% of our cohort had NEC as opposed
to 24–30.8% in other paediatric IF populations20 36), may in part
explain this low survival rate although numbers of patients are
admittedly small. It is of note that of our population referred to
the NST very early (,3 months of age), primarily because of
early-onset cholestasis, have a particularly poor prognosis
(survival 33% compared with 88% if >3 months) and would
have been omitted from other published cohorts of this
condition (table 3).14 The 88% survival rate of those infants
referred at or after 3 months of age is comparable to the survival
data reported from large single-centre HPN programmes, such
as the 81% survival rate in 302 patients reported from Paris.34
CONCLUSIONS
The economic impact of HPN for paediatric patients is high.37
The cost-effectiveness of CSBLT versus long-term HPN is not
clear,38 and is a somewhat artificial argument in light of donor
organ shortage for the paediatric population. Local factors (high
incidence of NEC) may contribute to our high use of HPN. The
Table 4 Outcome statistics according to patient characteristics
Comparator Survival (%) Significance
NEC vs non-NEC 8/11 (73%) vs 4/12 (34%) p = 1.000
Age ,3/12 vs >3/12 at referral 4/12 (33%) vs 9/11 (81%) p = 0.036
Preterm vs non-preterm 9/15 (60%) vs 4/8 (50%) p = 0.685
HPN vs non-HPN 10/13 (77%) vs 3/10 (30%) p = 0.040
Cholestatic vs non-cholestatic at referral 8/14 (57%) vs 5/9 (55%) p = 1.000
Residual bowel length >40 cm vs ,40 cm 9/11 (82%) vs 2/7 (28%) p = 0.049
ICV intact vs ICV removal 6/10 (60%) vs 5/8 (63%) p = 1.000
Infection rate ,30 days vs >30 days 2/9 (22%) vs 10/15 (66%) p = 0.089
HPN, home parenteral nutrition; ICV, ileo-caecal valve; NEC, necrotising enterocolitis.
Figure 1 Comparison of Royal Hospital for Sick Children, Edinburgh
(RHSC) regional data and extrapolation to national situation in terms of
home parenteral nutrition (HPN) registration18 and indication for referral
to combined small bowel and liver transplantation (CSBLT) services15
expressed as patients per year.
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registration of paediatric HPN to the BANS registry is not
compulsory and therefore these data are likely to be incomplete.
However, the great excess in our series of HPN usage and
indications for CSBLT services, compared with nationally
collected data15 18 strongly suggest that, nationally, patients
may be lost due to early death, discontinuation of care, or non-
referral, prior to reaching regional paediatric gastroenterology
services, let alone transplantation services. Outcomes data are
vital for service planning, but must reflect the full spectrum of
the clinical arena; we suggest that with firmer establishment of
managed clinical networks for paediatric nutrition support, that
the patterns of care for IF patients in the UK will increasingly
mirror the current practice in our region in terms of ascertain-
ment and outcomes, with full referral of all cases of IF from
early neonatal life. Such data may be of importance both when
counselling parents and for future planning of regional IF and
national transplant services. Our data also suggest there may be
greater need for ILT and CSBLT assessment than currently
recognised, and we suggest that the ongoing further national
surveillance of IF may clarify the current position (BIFS study
http://bspghan.org.uk/working_groups/nutrition.shtml).
The treatment of IF in the paediatric population remains a
therapeutic challenge for the future. These patients have highly
specialised needs, best served by tertiary care units where
sufficient surgical, medical, dietetic and nursing expertise for
their management can be developed yet delivered closer to
home. Overall throughput is low in terms of numbers, even in
large centres. This makes randomised controlled trials of
therapies difficult to organise in terms of feasibility. In the
absence of a robust evidence base, standardisation of care with
clinical guidelines for PN usage22 together with dissemination of
skills through managed clinical networks are the best current
ways to optimise care. Close working relationships between
regional tertiary units and the central transplant centres is of
particular importance. Patient populations in the regional centres
may differ from the experience of intestinal transplantation units;
sharing and honest appraisal of patient outcomes between
regional and intestinal transplantation centres may also help the
counselling of parents, regional and national service planning for
both HPN and intestinal transplant services, and long-term
outcomes for these patients within the UK.
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